Cancer Antigen (CA) test is used to diagnose various disease such as cancer, uterine fibroids, endometriosis, and liver disease. CA 125 is a protein that is found in the blood. The test is mostly widely used of the diagnosis of ovarian cancer in women. Normal levels of CA 125 in the blood is less 30 units per ml. and elevated levels for CA 125 signals the presence cancer in the ovary. Besides diagnosis, the CA 125 test is also used for monitoring ovarian cancer, as well as for screening ovarian cancer in women suspected to be at high risk for developing the disease.
Increasing demand for cancer diagnosis and treatment services, rising prevalence of cancer among the women and increasing emphasis on women healthcare. Furthermore, extensive diagnostic tests for cancer, also fuel the market growth. The growth of the market is restrained by the high cost of devices used in cancer diagnostics.
According to the American Cancer Society, in 2015, ovarian cancer represents only 3% of all malignancies in the U.S. women. Also there is a rise in the death rate due to various types of cancer of reproductive tract in women. Additionally, in the U.S., 22,280 women were estimated to have received an ovarian cancer diagnostic services and 14,240 deaths.
Segments
The global CA 125 test market is segmented on the basis of devices and accessories, devices, and end user.
On the basis of devices and accessories, market is segmented into spectrometer, analyzer, sample collection tubes, isotopic labeled peptides, and others.
On the basis of indication, the market is segmented into cancer, uterine fibroids, endometriosis, liver diseases, and others. Cancer is further segmented into ovarian cancer, endometrial cancer, fallopian tube cancer, stomach cancer, breast cancer, and others.
On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Key Players in the Global CA 125 Test Market
Some of the key players in this market are Allergan plc. (U.K), Amgen Inc. (U.S.), Bayer (Germany), BD (U.S.), Eli Lilly Company (U.S.) , Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Private Limited (Israel), AMAG Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Sanofi (France), Novartis (Germany), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (U.S.), and others.